Seniors Integrated Longitudinal cardioVascular Evaluation of Coronary Heart Disease: a Multicenter, Prospective Registry in China (SILVER-China)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age75+
SponsorBeijing Hospital

About this trial

This study aims to establish a nationwide cohort and biobank of elderly patients with coronary heart disease (CHD) and to develop risk prediction models and clinical treatment optimization plans based on this data. The specific research content is as follows:

The Study plan to continuously enroll hospitalized elderly CHD patients across 50 centers nationwide. Using networked electronic data collection technology, standardized methods and protocols will be used to gather demographic information (such as age, gender, education level, income, etc.), clinical information (medical history, past treatment records, current treatment plans, surgical records, medication use, etc.), lifestyle information (dietary habits, exercise frequency, smoking, drinking, etc.), biological information (such as inflammatory markers, etc.), and physical examination data (such as blood pressure, ECG, sleep monitoring, imaging examinations, etc.). These patients will be followed up long-term (1 month, 6 months, 1 year, and annually thereafter for up to 5 years) to establish a database that meets international standards. Centers meeting the criteria will also retain biological samples, creating a multicenter biobank for elderly CHD patients.

Second, based on the established clinical cohort, a risk prediction model for elderly CHD patients will be developed, including mortality risk, ischemic risk, bleeding risk, etc. Additionally, optimized clinical diagnostic and treatment plans will be formulated to improve the treatment outcomes and quality of life for elderly CHD patients. This research is expected to provide scientific evidence and technical support for the prevention, diagnosis, and treatment of CHD in elderly patients.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

This time he was admitted to the hospital due to angina pectoris and other coronary heart disease-related symptoms

This admission was performed for coronary angiography, coronary artery CTA confirmed coronary heart disease;

Previous clear coronary angiography, coronary artery Coronary heart disease diagnosed by imaging evidence such as CTA evidence;

The attending physician according to the patient's symptoms, medical history, myocardial injury markers, electrocardiogram, echo cardiography, myocardial radionuclide imaging, etc. diagnosed coronary heart disease.

Disqualifiers

Combined with severe non-cardiovascular disease: life expectancy does not exceed 6 months, such as advanced cancer or other end-stage disease;

Unable to cooperate with long-term follow-up: such as patients with severe cognitive impairment or severe mental illness; ③ Non-cardiogenic death within 24 hours after admission.

Trial population

This project aims to establish a nationwide cohort of elderly patients with coronary heart disease. Elderly inpatients with coronary heart disease who met the admission criteria were selected into 50 centers across the country. To ensure the representativeness of the sample, the study will adopt the following strategies: extensive coverage of different regions: select medical institutions in major geographical regions of the country to ensure geographical diversity and regional representativeness of the data; Covering different types of medical institutions ensures that patients at different levels of medical services can be included in the study.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

10,139 Participants
are grouped into 1 trial group
Group A: Elderly patients with coronary heart disease

Trial outcomes

Primary outcomes

1

major adverse cardiovascular events

MACCE, refers to the composite endpoint including all-cause mortality, non-fatal myocardial infarction, non-fatal stroke, and ischemia-driven revascularization

Time frame
From enrollment to the end of follow up at 5 years

Secondary outcomes

1

all-cause mortality

Time frame
From enrollment to the end of follow up at 5 years
2

cardiogenic death

Time frame
From enrollment to the end of follow up at 5 years
3

non-fatal myocardial infarction

Time frame
From enrollment to the end of follow up at 5 years
4

non-fatal stroke and ischemia-driven revascularization

Time frame
From enrollment to the end of follow up at 5 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.